Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Definitive Healthcare Analyst Ratings and Price Targets | NASDAQ:DH | Benzinga
Definitive Healthcare Corp has a consensus price target of $7.39 based on the ratings of 16 analysts. The high is $17 issued by Morgan Stanley on February 28, 2023. The low is $3 issued by Barclays on March 3, 2025. The 3 most-recent analyst ratings were released by Goldman Sachs, Goldman Sachs, and Barclays on May 12, 2025, March 4, 2025, and March 3, 2025, respectively. With an average price target of $3.13 between Goldman Sachs, Goldman Sachs, and Barclays, there's an implied -3.14% downside for Definitive Healthcare Corp from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Goldman Sachs
Barclays
Stephens & Co.
BTIG
Deutsche Bank
1calculated from analyst ratings
Analyst Ratings for Definitive Healthcare
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/12/2025 | Buy Now | 5.1% | Goldman Sachs | Kash Rangan70% | $3 → $3.4 | Maintains | Neutral | Get Alert |
| 03/04/2025 | Buy Now | -7.26% | Goldman Sachs | Kash Rangan70% | $4.5 → $3 | Maintains | Neutral | Get Alert |
| 03/03/2025 | Buy Now | -7.26% | Barclays | Saket Kalia78% | $4 → $3 | Maintains | Underweight | Get Alert |
| 01/16/2025 | Buy Now | — | Needham | Ryan MacDonald62% | — | Reiterates | Hold → Hold | Get Alert |
| 01/13/2025 | Buy Now | 23.65% | Barclays | Saket Kalia78% | $4 → $4 | Downgrade | Equal-Weight → Underweight | Get Alert |
| 12/20/2024 | Buy Now | 54.56% | Stephens & Co. | Jeff Garro41% | → $5 | Initiates | → Equal-Weight | Get Alert |
| 11/08/2024 | Buy Now | — | Needham | Ryan MacDonald62% | — | Reiterates | → Hold | Get Alert |
| 09/17/2024 | Buy Now | 116.38% | BTIG | David Larsen45% | → $7 | Initiates | → Buy | Get Alert |
| 08/09/2024 | Buy Now | 54.56% | Deutsche Bank | George Hill62% | $7 → $5 | Maintains | Hold | Get Alert |
| 08/07/2024 | Buy Now | 23.65% | Barclays | Saket Kalia78% | $6 → $4 | Maintains | Equal-Weight | Get Alert |
| 08/07/2024 | Buy Now | 54.56% | Baird | Vikram Kesavabhotla54% | $6 → $5 | Maintains | Neutral | Get Alert |
| 08/06/2024 | Buy Now | 54.56% | Morgan Stanley | Craig Hettenbach74% | $9 → $5 | Maintains | Equal-Weight | Get Alert |
| 08/06/2024 | Buy Now | — | Needham | Ryan MacDonald62% | — | Reiterates | → Hold | Get Alert |
| 07/31/2024 | Buy Now | 131.84% | Stifel | David Grossman65% | $9.5 → $7.5 | Maintains | Buy | Get Alert |
| 07/31/2024 | Buy Now | 85.47% | Barclays | Saket Kalia78% | $7 → $6 | Maintains | Equal-Weight | Get Alert |
| 07/31/2024 | Buy Now | 85.47% | Baird | Vikram Kesavabhotla54% | $8 → $6 | Maintains | Neutral | Get Alert |
| 07/31/2024 | Buy Now | 54.56% | JP Morgan | Anne Samuel50% | $7 → $5 | Downgrade | Neutral → Underweight | Get Alert |
| 07/31/2024 | Buy Now | — | Needham | Ryan MacDonald62% | — | Reiterates | → Hold | Get Alert |
| 05/09/2024 | Buy Now | 116.38% | Deutsche Bank | George Hill62% | $10 → $7 | Maintains | Hold | Get Alert |
| 05/09/2024 | Buy Now | 116.38% | Barclays | Saket Kalia78% | $11 → $7 | Maintains | Equal-Weight | Get Alert |
| 05/08/2024 | Buy Now | 147.3% | Canaccord Genuity | David Hynes62% | $10 → $8 | Maintains | Hold | Get Alert |
| 05/08/2024 | Buy Now | 193.66% | Stifel | David Grossman65% | $11 → $9.5 | Maintains | Buy | Get Alert |
| 05/08/2024 | Buy Now | — | Needham | Ryan MacDonald62% | — | Reiterates | → Hold | Get Alert |
| 05/08/2024 | Buy Now | 178.21% | Morgan Stanley | Craig Hettenbach74% | $11.5 → $9 | Downgrade | Overweight → Equal-Weight | Get Alert |
| 03/01/2024 | Buy Now | 240.03% | Barclays | Saket Kalia78% | $10 → $11 | Maintains | Equal-Weight | Get Alert |
| 02/29/2024 | Buy Now | 209.12% | Canaccord Genuity | David Hayes52% | $9 → $10 | Maintains | Hold | Get Alert |
| 01/17/2024 | Buy Now | — | Needham | Ryan MacDonald62% | — | Downgrade | Buy → Hold | Get Alert |
| 01/17/2024 | Buy Now | 240.03% | Stifel | David Grossman65% | $12 → $11 | Maintains | Buy | Get Alert |
| 01/05/2024 | Buy Now | 209.12% | Canaccord Genuity | David Hayes52% | → $10 | Downgrade | Buy → Hold | Get Alert |
| 11/03/2023 | Buy Now | 193.66% | Morgan Stanley | Craig Hettenbach74% | $15.5 → $9.5 | Maintains | Overweight | Get Alert |
| 08/16/2023 | Buy Now | 224.57% | Goldman Sachs | Kash Rangan70% | $17 → $10.5 | Maintains | Neutral | Get Alert |
| 08/15/2023 | Buy Now | 270.94% | Canaccord Genuity | David Hayes52% | $13 → $12 | Maintains | Buy | Get Alert |
| 08/15/2023 | Buy Now | 363.68% | Morgan Stanley | Craig Hettenbach74% | $17 → $15 | Maintains | Overweight | Get Alert |
| 08/15/2023 | Buy Now | 224.57% | B of A Securities | Allen Lutz52% | $12 → $10.5 | Maintains | Neutral | Get Alert |
| 08/15/2023 | Buy Now | 363.68% | Needham | Ryan MacDonald62% | → $15 | Reiterates | Buy → Buy | Get Alert |
| 08/01/2023 | Buy Now | 363.68% | Needham | Ryan MacDonald62% | → $15 | Reiterates | Buy → Buy | Get Alert |
| 07/24/2023 | Buy Now | 301.85% | Baird | Vikram Kesavabhotla54% | → $13 | Downgrade | Outperform → Neutral | Get Alert |
| 06/16/2023 | Buy Now | 363.68% | Needham | Ryan MacDonald62% | → $15 | Reiterates | → Buy | Get Alert |
| 05/08/2023 | Buy Now | 209.12% | Barclays | Saket Kalia78% | $11 → $10 | Maintains | Equal-Weight | Get Alert |
| 05/05/2023 | Buy Now | 240.03% | B of A Securities | Allen Lutz52% | → $11 | Maintains | Neutral | Get Alert |
| 05/05/2023 | Buy Now | 270.94% | Credit Suisse | Jonathan Yong66% | $15 → $12 | Maintains | Neutral | Get Alert |
| 05/05/2023 | Buy Now | 363.68% | Needham | Ryan MacDonald62% | → $15 | Reiterates | → Buy | Get Alert |
| 04/19/2023 | Buy Now | — | William Blair | Ryan Daniels20% | — | Initiates | → Outperform | Get Alert |
| 02/28/2023 | Buy Now | 425.5% | Morgan Stanley | — | $18 → $17 | Maintains | Overweight | Get Alert |
| 02/24/2023 | Buy Now | 363.68% | Credit Suisse | Jonathan Yong66% | $19 → $15 | Maintains | Neutral | Get Alert |
| 02/24/2023 | Buy Now | 363.68% | Needham | Ryan MacDonald62% | → $15 | Reiterates | → Buy | Get Alert |
| 01/06/2023 | Buy Now | 456.41% | Morgan Stanley | Craig Hettenbach74% | $21 → $18 | Maintains | Overweight | Get Alert |
| 11/07/2022 | Buy Now | 425.5% | Goldman Sachs | Kash Rangan70% | $31 → $17 | Maintains | Neutral | Get Alert |
| 11/04/2022 | Buy Now | 549.15% | Morgan Stanley | Craig Hettenbach74% | $23 → $21 | Maintains | Overweight | Get Alert |
| 11/04/2022 | Buy Now | 487.33% | Credit Suisse | Jonathan Yong66% | $24 → $19 | Maintains | Neutral | Get Alert |
| 11/04/2022 | Buy Now | 363.68% | Needham | Ryan MacDonald62% | $32 → $15 | Maintains | Buy | Get Alert |
| 10/24/2022 | Buy Now | 610.97% | Morgan Stanley | Craig Hettenbach74% | $34 → $23 | Maintains | Overweight | Get Alert |
| 08/08/2022 | Buy Now | 951% | Morgan Stanley | Craig Hettenbach74% | $37 → $34 | Maintains | Overweight | Get Alert |
| 08/08/2022 | Buy Now | 610.97% | Barclays | Saket Kalia78% | $24 → $23 | Maintains | Equal-Weight | Get Alert |
| 07/06/2022 | Buy Now | 827.36% | Needham | Ryan MacDonald62% | → $30 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for Definitive Healthcare (DH) stock?
The latest price target for Definitive Healthcare (NASDAQ:DH) was reported by Goldman Sachs on May 12, 2025. The analyst firm set a price target for $3.40 expecting DH to rise to within 12 months (a possible 5.10% upside). 18 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Definitive Healthcare (DH)?
The latest analyst rating for Definitive Healthcare (NASDAQ:DH) was provided by Goldman Sachs, and Definitive Healthcare maintained their neutral rating.
When was the last upgrade for Definitive Healthcare (DH)?
There is no last upgrade for Definitive Healthcare
When was the last downgrade for Definitive Healthcare (DH)?
The last downgrade for Definitive Healthcare Corp happened on January 13, 2025 when Barclays changed their price target from $4 to $4 for Definitive Healthcare Corp.
When is the next analyst rating going to be posted or updated for Definitive Healthcare (DH)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Definitive Healthcare, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Definitive Healthcare was filed on May 12, 2025 so you should expect the next rating to be made available sometime around May 12, 2026.
Is the Analyst Rating Definitive Healthcare (DH) correct?
While ratings are subjective and will change, the latest Definitive Healthcare (DH) rating was a maintained with a price target of $3.00 to $3.40. The current price Definitive Healthcare (DH) is trading at is $3.24, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
